Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03722-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Sitah Alharthi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi, 11961, Saudi Arabia. Hauptthemen laut MEDLINE: Dendritic Cells, Mice, Inbred C57BL, Polyethylene Glycols, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study aims to utilize PEGylated poly (lactic-co-glycolic acid) (PLGA) nanoparticles as a delivery system for simultaneous administration of the BRAFV600E peptide, a tumor-specific antigen, and imiquimod (IMQ). The objective is to stimulate dendritic cell (DC) maturation, activate macrophages, and facilitate antigen presentation in C57BL6 mice. METHODS: PEG-PLGA-IMQ-BRAFV600E nanoparticles were synthesized using a PLGA-PEG-PLGA tri-block copolymer, BRAFV600E, and IMQ. Characterization included size measurement and drug release profiling. Efficacy was assessed in inhibiting BPD6 melanoma cell growth and activating immature bone marrow DCs, T cells, macrophages, and splenocyte cells through MTT and ELISA assays. In vivo, therapeutic and immunogenic effects potential was evaluated, comparing it to IMQ + BRAFV600E and PLGA-IMQ-BRAFV600E nanoparticles in inhibiting subcutaneous BPD6 tumor growth. RESULTS: The results highlight the successful synthesis of PEG-PLGA-IMQ-BRAFV600E nanoparticles (203 ± 11.1 nm), releasing 73.4% and 63.2% of IMQ and BARFV600E, respectively, within the initial 48 h. In vitro, these nanoparticles demonstrated a 1.3-fold increase in potency against BPD6 cells, achieving ~ 2.8-fold enhanced cytotoxicity compared to PLGA-IMQ-BRAFV600E. Moreover, PEG-PLGA-IMQ-BRAFV600E exhibited a 1.3-fold increase in potency for enhancing IMQ cytotoxic effects and a 1.1- to ~ 2.4-fold increase in activating DCs, T cells, macrophages, and splenocyte cells compared to IMQ-BRAFV600E and PLGA-IMQ-BRAFV600E. In vivo, PEG-PLGA-IMQ-BRAFV600E displayed a 1.3- to 7.5-fold increase in potency for inhibiting subcutaneous BPD6 tumor growth compared to the other formulations. CONCLUSIONS: The findings suggest that PEG-PLGA nanoparticles effectively promote DC maturation, T cell activation, and potentially macrophage activation. The study highlights the promising role of this nanocomposite in vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi, 11961, Saudi Arabia.
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, 7718175911, Iran.
- Nishtar Medical University and Hospital, Multan, 60000, Pakistan.
- School of Pharmacy, Fudan University, Shanghai, 201203, PR China.
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, 7718175911, Iran. ebrahimi@rums.ac.ir.
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, 7718175911, Iran. s.ebrahimalavi@gmail.com.
Zitieren
APA
Alharthi, S., Alavi, S. Z., Nisa, M. U., Koohi, M., Raza, A., Ebrahimi Shahmabadi, H., & Alavi, S. E. (2024). Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03722-1
Vancouver
Alharthi S, Alavi SZ, Nisa MU, Koohi M, Raza A, Ebrahimi Shahmabadi H, et al. Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03722-1
BibTeX
@article{Alharthi2024,
author = {Alharthi, Sitah and Alavi, Seyed Zeinab and Nisa, Mehr Un and Koohi, Maedeh and Raza, Aun and Ebrahimi Shahmabadi, Hasan and Alavi, Seyed Ebrahim},
title = {Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03722-1}
}
EUVIMED